arginyl-tRNA synthetase 2, mitochondrial
Zuletzt aktualisiert 18. Aug 2020
Erfüllt die redaktionelle Richtlinien
- HerunterladenHerunterladen
- Teilen
- Language
- Diskussion
- Ask Patient
- Audio-Version
- Zu bevorzugten Quellen bei Google hinzufügen
Der RARS2 gene provides instructions for making an enzyme called mitochondrial arginyl-tRNA synthetase. This enzyme is active in cell structures called mitochondria. Each cell contains hundreds or thousands of mitochondria, which convert the energy from food into a form that cells can use.
Normal function
Der RARS2 gene provides instructions for making an enzyme called mitochondrial arginyl-tRNA synthetase. This enzyme is active in cell structures called mitochondria. Each cell contains hundreds or thousands of mitochondria, which convert the energy from food into a form that cells can use.
Mitochondrial arginyl-tRNA synthetase interacts with a molecule called transfer RNA (tRNA). This molecule, which is a chemical cousin of DNA, helps assemble protein building blocks called amino acids into functioning proteins. To build new proteins, tRNA must collect different amino acids and then attach them to one another in the correct order. Mitochondrial arginyl-tRNA synthetase is one of several enzymes that link amino acids to tRNA. Specifically, this enzyme links the amino acid arginine to the tRNA molecule, which then incorporates it into new proteins in mitochondria.
Conditions referring to this gene or chromosome
Other names
arginine-tRNA ligase
arginyl-tRNA synthetase 2, mitochondrial precursor
arginyl-tRNA synthetase-like
ArgRS
DALRD2
dJ382I10.6
MGC14993
MGC23778
PRO1992
RARSL
SYRM_HUMAN
Related patient information and medicines

Patient information leaflet
Muskelschwäche
Examples include: Glycogen storage diseases Blood glucose test (blood sugar) and HbA1c (in which glycogen, a carbohydrate, infiltrates muscles as well as other organs). Even rarer, mitochondrial diseases which occur when the energy systems inside muscle cells don't work properly. A doctor may need to test the central nervous system, including.

Patient information leaflet
Zyklisches Erbrechensyndrom
Zyklisches Erbrechensyndrom is a condition which occurs mainly in children but can also affect adults. It is more common in people who have migraines. The relationship between cyclical vomiting syndrome and migraines is well recognised. Some studies have suggested a link between cyclical vomiting syndrome and autonomic disturbances or mitochondrial.

Patient information leaflet
Pfeiffersches Drüsenfieber
Glandular fever (also known as infectious mononucleosis) ist ein viral Infektion that most often affects teenagers and young adults. Although it can make some people feel quite ill, full recovery is usual. What is glandular fever. Glandular fever is a viral infection, mostly caused by the Epstein-Barr virus. The virus can be passed from person to.

Patient information leaflet
Impfung gegen Grippe
Getting the flu vaccine is a safe and effective way to protect against becoming seriously ill with flu. Some people can become seriously ill with flu, needing hospital treatment, and it can be life-threatening. Certain groups of people, such as older adults and young children, are at higher risk from flu infection. Getting the flu vaccine reduces.

Patient information leaflet
Find out if you are eligible for a free NHS flu vaccination
Open the flu jab Is the flu vaccine free for you this winter. The flu vaccine is free on the NHS for people most likely to get seriously ill from flu, and for those who could easily pass it on to someone at risk. Whether you qualify depends on your age, your health, and a few other things such as being pregnant or caring for someone. The groups.

Patient information leaflet
Behandlung von Typ-2-Diabetes
Although Diabetes cannot be cured, it can be treated successfully. If a high blood sugar level is brought down to a normal level, your symptoms will ease and your risk of long-term complications will be much lower. Managing type 2 diabetes Keeping your blood sugar (glucose) well controlled is key to reducing your risk of long-term complications.
Weiterführende Lektüre und Referenzen
- arginyl-tRNA synthetase 2, mitochondrial; MedlinePlus, National Library of Medicine.
- Cassandrini D, Cilio MR, Bianchi M, Doimo M, Balestri M, Tessa A, Rizza T, Sartori G, Meschini MC, Nesti C, Tozzi G, Petruzzella V, Piemonte F, Bisceglia L, Bruno C, Dionisi-Vici C, D'Amico A, Fattori F, Carrozzo R, Salviati L, Santorelli FM, Bertini E. Pontocerebellar hypoplasia type 6 caused by mutations in RARS2: definition of the clinical spectrum and molecular findings in five patients. J Inherit Metab Dis. 2013 Jan;36(1):43-53. doi: 10.1007/s10545-012-9487-9. Epub 2012 May 8.
- Edvardson S, Shaag A, Kolesnikova O, Gomori JM, Tarassov I, Einbinder T, Saada A, Elpeleg O. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am J Hum Genet. 2007 Oct;81(4):857-62. doi: 10.1086/521227. Epub 2007 Aug 24.
- Glamuzina E, Brown R, Hogarth K, Saunders D, Russell-Eggitt I, Pitt M, de Sousa C, Rahman S, Brown G, Grunewald S. Further delineation of pontocerebellar hypoplasia type 6 due to mutations in the gene encoding mitochondrial arginyl-tRNA synthetase, RARS2. J Inherit Metab Dis. 2012 May;35(3):459-67. doi: 10.1007/s10545-011-9413-6. Epub 2011 Nov 16.
- Namavar Y, Barth PG, Kasher PR, van Ruissen F, Brockmann K, Bernert G, Writzl K, Ventura K, Cheng EY, Ferriero DM, Basel-Vanagaite L, Eggens VR, Krageloh-Mann I, De Meirleir L, King M, Graham JM Jr, von Moers A, Knoers N, Sztriha L, Korinthenberg R; PCH Consortium; Dobyns WB, Baas F, Poll-The BT. Clinical, neuroradiological and genetic findings in pontocerebellar hypoplasia. Brain. 2011 Jan;134(Pt 1):143-56. doi: 10.1093/brain/awq287. Epub 2010 Oct 15.
Artikelverlauf
Artikel auch verfügbar in Englisch, Deutsch, Spanisch, Französisch, Italienisch, Portugiesisch, Hindi, Hebräisch, Arabisch, und Schwedisch.
18. Aug 2020 | Neueste Version
1 Nov 2014 | Ursprünglich veröffentlicht
Teilen Sie Ihre Gedanken oder Erfahrungen mit anderen in unserem Patientengemeinschaften.
Abonnieren Sie den Patienten-Newsletter
Ihre wöchentliche Dosis klarer, vertrauenswürdiger Gesundheitsberatung - geschrieben, um Ihnen zu helfen, sich informiert, selbstbewusst und in Kontrolle zu fühlen.
Durch das Abonnieren akzeptieren Sie unsere Datenschutzrichtlinie. Sie können sich jederzeit abmelden. Wir verkaufen Ihre Daten niemals.

